Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China

BMC Medical Genetics

Volumn 10, Issue , 2009, Pages

  Bai, Yongheng ^a   Yu, Yaping ^b   Yu, Bin ^b   Ge, Jianrong ^b   Ji, Jingzhang ^c   Lu, Hong ^c   Wei, Jia ^a   Weng, Zhiliang ^a   Tao, Zhihua ^c   Lu, Jianxin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b SHAOXING UNIVERSITY   (China)

^c THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN APA1; PROTEIN BSM1; PROTEIN FOK1; PROTEIN TAQ1; PROTEIN TRU91; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER STAGING; CHINA; CONTROLLED STUDY; EXON; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HAPLOTYPE; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; PROSTATE CANCER; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; CASE CONTROL STUDY; ETHNIC GROUP; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PROSTATE TUMOR; RISK; RISK FACTOR; STATISTICAL MODEL;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHINA; ETHNIC GROUPS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK FACTORS;

EID: 73249116648     PISSN: None     EISSN: 14712350     Source Type: Journal    
DOI: 10.1186/1471-2350-10-125     Document Type: Article

References (38)

1. American Cancer Society Cancer Facts and Figures 2003, , http://www.cancer.org/docroot/home/index.asp
2. Quinn M, Babb P. Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 2002, 90:162-173. 10.1046/j.1464-410X.2002.2822.x, 12081758.
3. Ostrander EA, Stanford JL. Genetics of prostate cancer: too many loci, too few genes. Am J Hum Genet 2000, 67:1367-1375. 10.1086/316916, 1287913, 11067781.
4. The incidence of cancer in Shanghai city in 1983-2005. Tumor 2008, 28:571.
5. Gu FL. Changing constituents of genitourinary cancer in recent 50 years in Beijing. Chin Med J (Eng l) 2003, 116:1391-1393.
6. Zhang HF, Wang HL, Xu N, Li SW, Ji GY, Li XM, Pang YZ, Zhang L, Zhao XJ, Gao HW. Mass screening of 12027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J (Eng l) 2004, 117:67-70.
7. Schwartz GG, Hulka BS. Is vitamin D deficiency a risk factor for prostate cancer? (hypothesis). Anticancer Res 1990, 10:1307-1311.
8. Hanchette CL, Schwartz GG. Geographic patterns of prostate cancer mortality: evidence for a protective effect of ultraviolet radiation. Cancer (Phila.) 1992, 70:2861-2869.
9. Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S, Hedlund TE, Upadhya P. The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1a,25 dihydroxyvitamin D3. Cancer Res 1992, 52:515-520.
10. Peehl DM, Skowronski RJ, Leung GK, Wong ST, Stamey TA, Feldman D. Antiproliferative effects of 1,25-dihydroxyvitamin D3 on primary cultures of human prostatic cells. Cancer Res 1994, 54:805-810.
11. Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP. 1a,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 1997, 6:727-732.
12. Guzey M, Kitada S, Reed JC. Apoptosis induction by 1alpha, 25-dihydroxyvitamin D3 in prostate cancer. Mol Cancer Ther 2002, 1:667-677.
13. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994, 367:284-287. 10.1038/367284a0, 8161378.
14. Saijo T, Ito M, Takeda E, Huq AH, Naito E, Yokota I, Sone T, Pike JW, Kuroda Y. A unique mutation in the vitamin D receptor gene in three Japanese patients with vitamin D-dependent rickets type II: utility of single-strand conformation polymorphism analysis for heterozygous carrier detection. Am J Hum Genet 1991, 49:668-673. 1683124, 1652893.
15. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E, Pike JW. Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 1997, 11:1165-1179. 10.1210/me.11.8.1165, 9212063.
16. Arai H, Miyamoto K, Taketani Y, Yamamoto H, Iemori Y, Morita K, Tonai T, Nishisho T, Mori S, Takeda E. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997, 12:915-921. 10.1359/jbmr.1997.12.6.915, 9169350.
17. Taylor JA, Hirvonen A, Watson M, Pittman G, Mohler JL, Bell DA. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996, 56:4108-4110.
18. Ingles SA, Ross RK, Yu MC, Irvine RA, La Pera G, Haile RW, Coetzee GA. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst (Bethesda) 1997, 89:166-170.
19. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM. Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 2003, 12:23-27.
20. Habuchi T, Suzuki T, Sasaki R, Wang L, Sato K, Satoh S, Akao T, Tsuchiya N, Shimoda N, Wada Y, Koizumi A, Chihara J, Ogawa O, Kato T. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res 2000, 60:305-308.
21. Cheteri MB, Stanford JL, Friedrichsen DM, Peters MA, Iwasaki L, Langlois MC, Feng Z, Ostrander EA. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate 2004, 59:409-418. 10.1002/pros.20001, 15065089.
22. Medeiros R, Morais A, Vasconcelos A, Costa S, Pinto D, Oliveira J, Lopes C. The role of vitamin D receptor gene polymorphisms in the susceptibility to prostate cancer of a southern European population. J Hum Genet 2002, 47:413-418. 10.1007/s100380200060, 12181642.
23. John EM, Schwartz GG, Koo J, Den B, Ingles SA. Sun Exposure, Vitamin D Receptor Gene Polymorphisms, and Risk of Advanced Prostate Cancer. Cancer Res 2005, 65:5470-5479. 10.1158/0008-5472.CAN-04-3134, 15958597.
24. Patiyan A, Eberhard V, Peter S. Androgen receptor and vitamin D receptor gene polymorphisms and prostate cancer risk. Eur J Cancer 2006, 42:2833-2837. 10.1016/j.ejca.2006.06.030, 17010601.
25. Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, Halpern J, Balise RP, West DW, Paffenbarger J, Whittemore AS. Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 2004, 13:1325-1330.
26. Correa-Cerro L, Berthon P, Haussler J, Bochum S, Drelon E, Mangin P, Fournier G, Paiss T, Cussenot O, Vogel W. Vitamin D receptor polymorphisms as markers in prostate cancer. Hum Genet 1999, 105:281-287. 10.1007/s004390051102, 10987658.
27. Cicek MS, Liu X, Schumacher FR, Casey G, Witte JS. Vitamin D Receptor Genotypes/Haplotypes and Prostate Cancer Risk. Cancer Epidemiol Biomarkers Prev 2006, 15:2549-2552. 10.1158/1055-9965.EPI-06-0409, 17164384.
28. Ingles SA, Coetzee GA, Ross RK, Henderson BE, Kolonel LN, Crocitto L, Wang W, Haile RW. Association of prostate cancer with vitamin D receptor haplotype in African-Americans. Cancer Res 1998, 58:1620-1623.
29. Hayes VM, Severi G, Padilla EJ, Eggleton SA, Southey MC, Sutherland RL, Hopper JL, Giles GG. Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 2005, 14:997-999. 10.1158/1055-9965.EPI-04-0660, 15824177.
30. Berndt SI, Dodson JL, Huang WY, Nicodemus KK. A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 2006, 175:1613-1623. 10.1016/S0022-5347(05)00958-4, 16600714.
31. Yang Y, Wang S, Ye Z, Yang W. Association of single nucleotide polymorphism of vitamin D receptor gene start codon and the susceptibility to prostate cancer in the Han nationality in Hubei area. Zhonghua Nan Ke Xue 2004, 10:411-414.
32. Liu JH, Li HW, Wang JQ, Li M, Xin DQ, Na X, Zhang M, Ye SY, Na YQ. Vitamin D receptor gene BsmI polymorphism and the susceptibility to prostate cancer in northern Chinese Han population. Zhonghua Nan Ke Xue 2003, 9:413-416.
33. Chokkalingam AP, McGlynn KA, Gao YT, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res 2001, 61:4333-4336.
34. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974, 111:58-64.
35. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005, 15:97-98. 10.1038/sj.cr.7290286, 15740637.
36. Huang SP, Chou YH, Wayne C, Wu MT, Chen YY, Yu CC, Wu TT, Lee YH, Huang JK, Wu WJ, Huang CH. Association between vitamin D receptor gene polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett 2004, 207:69-77. 10.1016/j.canlet.2003.12.006, 15050735.
37. Ma J, Stampfer MJ, Gann PH, Hough HL, Giovannucci E, Kelsey KT, Hennekens CH, Hunter DJ. Vitamin D receptor polymorphisms, circulating vitamin D metabolites and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prev 1998, 7:385-390.
38. Morrison NA, Yeoman R, Kelly PJ, Eisman J. Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphisms and circulating osteocalcin. Proc Nail Acad Sci USA 1992, 89:6665-6669.